"Being a Scientist at Genentech provides the ultimate combination of advancing medicine to help patients and pursuing cutting-edge biomedical research."
I relocated to the US to pursue postdoctoral studies at the Scripps Research Institute with Dr. Bernard Gilula and thereafter in the department of Biochemistry and Biophysics at UCSF with Dr. Matthew Bogyo. Thereafter, I joined Celera Genomics and led the Chemical Proteomics group charged with providing biomarker support for small molecule programs in the areas of Cancer, Asthma and Autoimmune diseases.
I then joined KAI Pharmaceuticals and championed the preclinical research and development of therapeutic peptides for hyperparathyroidism in renal dialysis patients. The lead candidate from this effort was just recently launched.
I joined Genentech at the turn of 2011 as a Scientist in the OMNI Biomarker Development group.
EBioMedicine. 2015 May 30;2(7):730-43.
AAPS J. 2015 Jul;17(4):881-90.
In my role as Biomarker Team Leader, I develop and execute biomarker strategies for programs in several disease areas including metabolism, anti-microbial, ophthalmology and wound healing.